# US 2021/0275575 A1 · Composition for improving renal function in renal diseases containing molecular hydrogen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275575 A1
- Document ID: US20210275575A1
- Status: Published application
- Kind: A1
- Application number: 17/188,617
- Filed: 2021-03-01
- Published: 2021-09-09
- Earliest claimed: 2020-03-03
- Assignees: Miz Co., Ltd.
- Applicants: MiZ Company Limited
- Inventors: Fumitake SATOH; Ryosuke KUROKAWA; Hideyuki SASAKI; Yoshiaki SASAKI
- Web page: https://patentgrep.com/patent/US20210275575A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application provides a composition for improving or preventing human renal diseases, containing molecular hydrogen as an active ingredient, for example, a composition for improving or preventing renal diseases in a human patient having acute or chronic nephritis, renal failure, and/or nephrotic syndrome, for example, for improving urinary protein and urinary protein/urinary creatinine ratio to a normal range, and a method for improving renal diseases by administering the composition to the patient.

## Claims

### Claim 1

A method for preventing and/or improving a renal disease derived from human diabetes and/or hypertension in a human in need thereof, comprising administering to the human a composition comprising molecular hydrogen as an active ingredient.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the improvement of the renal disease is an improvement of acute or chronic nephritis, an improvement of renal failure, and/or an improvement of nephrotic syndrome.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the acute or chronic nephritis is selected from the group consisting of glomerulonephritis, interstitial nephritis, pyelonephritis, acute progressive glomerulonephritis, anti-glomerular basement membrane antibody nephritis, membranoproliferative glomerulonephritis, endocapillary proliferative glomerulonephritis, crescentic glomerulonephritis, and diabetic nephritis.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the improvement of the acute or chronic nephritis comprises improving urinary protein and urinary protein/urinary creatinine ratio to a normal range, or improving edema.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the normal range of urinary protein is less than 0.2 g/day, and the normal range of the urinary protein/urinary creatinine ratio is less than 0.3 g/gCr.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition is a gas composition comprising more than zero (0) and 18.5 vol % or less molecular hydrogen.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition is administered to the human by inhalation.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the composition is produced on the spot using a hydrogen generator.
